The anti-tumor effect in vivo did not correlate with an increased T cell infiltration since only a few CD4 or CD8 positive cells were observed in the MC38-C215 tumors at end-point without significant differences between control and tasquinimod treated tumors (unpublished observations). This evidence concerns the gene CD4 and neoplasm.